AYLAinactive

OLD AYALA, INC

Healthcare·Oncology·Phase 3
Oncology

OLD AYALA, INC (AYLA): 7 pipeline candidates · ~1 mo cash runway. Updated within the last hour.

7.2/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway0.3

1.1 months

Financial Health10.0

0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth10.0

7 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for OLD AYALA, INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

Cash

$2.7M

Quarterly Burn

$8.2M

Runway

1.1 mo

Revenue

$105K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jul 2026
Today~7 mo out
Catalyst within runway

Pipeline (7 candidates)

·CEO: Roni Mamluk, Ph.D.

Frequently asked questions

How many drug candidates are in OLD AYALA, INC's pipeline?

OLD AYALA, INC (AYLA) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is OLD AYALA, INC's lead drug candidate?

OLD AYALA, INC's most advanced tracked candidate is adxs-503 (Preclinical) for non-small cell lung cancer.

What is OLD AYALA, INC's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, OLD AYALA, INC has approximately 1.1 months of cash runway.

Who is the CEO of OLD AYALA, INC?

Roni Mamluk, Ph.D. is the chief executive officer of OLD AYALA, INC (AYLA).

Get the full picture on OLD AYALA, INC

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.